Unnati Pharmax

Ferinject Injection / Infusion
Composition: Ferric Carboxymaltose Solution for Injection / Infusion
International Trade Name: Ferinject®

Ferinject is a high-quality Ferric Carboxymaltose solution for injection or infusion, an intravenous iron preparation used for the rapid and effective treatment of iron deficiency and iron deficiency anemia. Manufactured in WHO-GMP certified facilities, Ferinject is supplied by trusted pharmaceutical exporters from India to support global hematology and critical care treatment programs.

Ferric Carboxymaltose is a stable iron complex that allows controlled delivery of bioavailable iron directly into the bloodstream. It replenishes iron stores efficiently, supports hemoglobin synthesis, and improves oxygen transport in the body. Ferinject enables high-dose iron administration in a short duration, ensuring faster correction of iron deficiency with a favorable safety profile.

Ferinject Injection / Infusion is primarily indicated for the treatment of iron deficiency anemia in patients who cannot tolerate oral iron, have poor absorption, or require rapid iron replenishment. It is commonly used in chronic kidney disease, heart failure, inflammatory bowel disease, postpartum anemia, and perioperative care. It is suitable for adult patients under medical supervision in hospital and clinical settings.

Ferinject Ferric Carboxymaltose Solution for Injection / Infusion is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The solution is supplied in secure, tamper-proof, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, dialysis centers, specialty clinics, government healthcare programs, and international pharmaceutical distributors.

Mito 10mg Injection
Composition: Mitomycin Injection 10mg
International Trade Name: Mutamycin®

Mito 10mg is a high-quality Mitomycin 10mg injection, an antineoplastic antibiotic used in the treatment of various types of cancer. Manufactured in WHO-GMP certified facilities, Mito Injection is supplied by trusted pharmaceutical exporters from India to support global oncology and chemotherapy treatment programs.

Mitomycin works by inhibiting DNA synthesis and cross-linking DNA strands, thereby preventing the growth and multiplication of cancer cells. Its potent cytotoxic action makes it effective in controlling tumor progression and reducing cancer cell proliferation in various malignancies.

Mito 10mg Injection is primarily indicated for the treatment of gastric cancer, pancreatic cancer, breast cancer, bladder cancer, and other solid tumors, either as a single agent or in combination with other chemotherapeutic drugs. It is suitable for adult patients under strict medical supervision in hospital and oncology care settings.

Mito 10mg Mitomycin Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, tamper-proof, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

BENDANYRA 100 Injection
Composition: Bendamustine Hydrochloride for Injection IP 100mg
International Trade Name: Treanda®

BENDANYRA 100 is a high-quality Bendamustine Hydrochloride 100mg injection, an alkylating antineoplastic agent used in the treatment of various hematological malignancies. Manufactured in WHO-GMP certified facilities, BENDANYRA Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and hematology treatment programs.

Bendamustine exhibits a unique mechanism of action by combining alkylating properties with purine analog-like activity, leading to DNA cross-linking, inhibition of DNA synthesis, and induction of cancer cell apoptosis. This dual action makes it highly effective against malignant lymphoid cells and certain resistant tumor types.

BENDANYRA 100 Injection is primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and multiple myeloma, either as monotherapy or in combination with other chemotherapeutic agents. It is suitable for adult patients under strict medical supervision in specialized oncology and hospital care settings.

BENDANYRA 100 Bendamustine Hydrochloride for Injection IP is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, tamper-proof, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

RAMCHLOBYRA 2 Tablets
Composition: Chlorambucil Tablets IP 2mg
International Trade Name: Leukeran®

RAMCHLOBYRA 2 is a high-quality Chlorambucil 2mg tablet formulation, an alkylating antineoplastic agent used in the treatment of various hematological malignancies. Manufactured in WHO-GMP certified facilities, RAMCHLOBYRA Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and hematology treatment programs.

Chlorambucil works by interfering with DNA replication and transcription in rapidly dividing cancer cells, leading to inhibition of cell growth and induction of apoptosis. Its cytotoxic action makes it effective in controlling the progression of certain leukemias and lymphomas.

RAMCHLOBYRA 2 Tablets are primarily indicated for the treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, non-Hodgkin’s lymphoma, and other lymphoproliferative disorders. They are suitable for adult patients under strict medical supervision, particularly in specialized oncology and hematology care settings.

RAMCHLOBYRA 2 Chlorambucil Tablets IP are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

DOXOBYRA Injection
Composition: Doxorubicin Hydrochloride Injection IP 50mg/25ml
International Trade Name: Adriamycin®, Doxil®, Caelyx®

DOXOBYRA is a high-quality Doxorubicin Hydrochloride injection, an anthracycline antineoplastic agent widely used in the treatment of various solid tumors and hematological malignancies. Manufactured in WHO-GMP certified facilities, DOXOBYRA Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology and chemotherapy treatment programs.

Doxorubicin works by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to the disruption of DNA replication and cancer cell death. This multi-mechanism cytotoxic action makes DOXOBYRA highly effective against rapidly dividing cancer cells and helps control tumor progression.

DOXOBYRA Injection is primarily indicated for the treatment of breast cancer, ovarian cancer, bladder cancer, lung cancer, soft tissue sarcomas, lymphomas, leukemias, and other malignancies, either as monotherapy or in combination chemotherapy regimens. It is suitable for adult patients under strict medical supervision in specialized oncology care settings.

DOXOBYRA Doxorubicin HCl Injection IP is manufactured under stringent GMP and oncology-grade quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, tamper-proof, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.